Every year, World Toilet Day is observed to raise awareness about the global sanitation crisis and encourage action to solve it. The goal set by the United Nation is to achieve safe toilets for all by 2023, as a part of their Sustainable Development Goals.
The UN also states that 3.5 billion people live without proper sanitation and many children also lose their lives due to poor sanitation and unsafe water. This is why World Toilet Day is observed to raise awareness on this issue.
This year, the theme for World Toilet Day 2024 is "Toilets - A Place for Peace'. This focuses on the growing threat to sanitation that is caused by conflict, climate change, disaster and neglect. When there is a threat to using toilets, it can lead to many health risks.
Not using toilets for too long may lead to Urinary Tract Infection or UTI. For many who do not have access to clean toilets do not drink enough liquid or hold pee for too long. Doctors suggest that holding in pee for too long can cause bacteria to multiply and lead to UTI. By not drinking enough water, your bladder fails to tell the body to pee often, and can cause the bacteria to spread through the urinary tract, which can lead to infection.
Holding in pee for too long can also cause your bladder to stretch, making it difficult or even impossible for the bladder to contract and release pee normally. It can also damage your pelvic floor muscles or could lead to kidney stones.
To prevent such conditions, it is important that everyone has access to clean and safe toilets. In terms of history, the day was established in 2001, by the World Toilet Organization (WTO), which was founded by Jack Sim. However, it was officially recognised by the UN in 2013. The Government of Singapore worked with WTO to create the first UN resolution called Sanitation for All.
India too promotes safe and hygiene toilet through its Swachh Bharat Yojna.
Credit: AI-generated image
The tiny particles of plastic found in food packaging, takeaway containers and almost everywhere in the environment may be quietly contributing to cancer risk. A new study has found that long-term exposure to microplastics could promote colorectal cancer, one of the deadliest forms of cancer.
The study published in Molecular Cancer recently found that exposure to polystyrene nanoplastics promoted tumour development in mice that were genetically at risk of colorectal cancer.
Researchers also observed growth of more tumours and more severe disease in animals exposed to microplastics than in those that were not exposed.
The findings offer a possible biological link between plastic pollution and cancer. However, the research has a limitation that it was conducted in animals, which means it did not conclusively prove that microplastics cause colon cancer.
Also read: Ivonescimab: Why Did US FDA Reject China's Promising Lung Cancer Drug?
Microplastics are plastic particles smaller than five millimetres, while nanoplastics are even tinier particles that are generally measured at the nanometre scale. They can enter the human body through food, drinking water and inhalation.
The latest research, conducted by scientists at Central South University in China, focused on polystyrene nanoplastics. Polystyrene is commonly used in disposable food containers, packaging materials and foam cups.
Researchers found that these particles accumulated predominantly in the colon of mice following long-term oral exposure. They also caused structural damage to the tiny, finger-like projections called microvilli that line the intestinal cells and help with nutrient absorption.
The exposure to microplastics not only disrupted the balance of gut bacteria but also affected the immune system's ability to fight tumour growth.
The researchers identified a mechanism that involved the gut microbiome, bacterial metabolites and immune cells. Exposure reduced levels of a beneficial bacterium called Faecalibaculum rodentium, which helped lower production of propionic acid, a short-chain fatty acid.
This reduction affected the activity of Th17 immune cells and the production of IL-17A, weakening an immune response involved in controlling tumour growth.
Also read: Russia's mRNA Cancer Vaccine: First Patient With Melanoma Completes Treatment, Shows No New Tumours
The researchers exposed the mice to a chemical treatment that causes colorectal cancer, which helped them investigate whether long-term exposure to nanoplastic exposure fueled tumour growth.
Animals exposed to polystyrene nanoplastics developed more tumours, with greater tumour severity, than those that were not exposed.
The findings suggest that nanoplastics may affect several processes involved in cancer development, including damage to the intestinal lining, changes in gut bacteria and changes in immune activity.
Also read: Microplastics Accumulation In Dementia Patients More Than Others, Study Finds
The researchers also examined human samples and detected different types of microplastics found in colorectal cancer tissues and blood.
This adds to earlier research investigating the presence of plastic particles in human tumours. A 2025 study reported higher concentrations of microplastics in colorectal tumour tissue than in nearby healthy tissue.
However, detecting microplastics in cancer tissue does not establish whether the particles contributed to tumour development. More human research is needed to understand this relationship.
The findings come amid growing concern about early-onset colorectal cancer, which refers to diagnoses in people younger than 50.
According to The Washington Post, colorectal cancer rates among adults aged 20 to 49 in the US increased by approximately 3% annually between 2013 and 2022.
Researchers have been investigating several possible reasons, including dietary patterns, sedentary behaviour, environmental exposures and changes in the gut microbiome.
However, microplastics remain one of several possible environmental contributors under investigation. There is currently insufficient evidence to attribute the rise in early-onset colorectal cancer to plastic exposure.
Completely avoiding microplastics can be challenging because they are widespread in the environment. However, some precautions can help reduce exposure.
Credit: iStock
Ivonescimab, a much-anticipated lung cancer drug developed by China's Akeso in partnership with US-based Summit Therapeutics, has been rejected by the US Food and Drug Administration (FDA).
The drug, a PD-1 x VEGF bispecific antibody, was being evaluated in combination with chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer had progressed after treatment with EGFR-targeted drugs.
The FDA's decision came after a late-stage clinical trial showed that ivonescimab significantly delayed disease progression but failed to demonstrate a statistically significant improvement in overall survival (OS), a key measure of how long patients live after starting treatment.
In its Complete Response Letter (CRL), the regulator said the improvement in progression-free survival (PFS), without a statistically significant OS benefit, "did not establish a favorable benefit-risk profile to support approval".
Also read: 1 In 5 US Lung Cancer Patients Never Smoked: Report Highlights Hidden Risk Factors
The FDA's decision was based on findings from the Phase III HARMONi trial, which compared ivonescimab plus platinum-based chemotherapy with chemotherapy alone.
The combination reduced the risk of disease progression or death by 48% compared with chemotherapy alone, meeting the trial's primary PFS endpoint.
However, the primary overall survival analysis did not demonstrate a statistically significant benefit. This meant that although patients receiving ivonescimab experienced a delay in their cancer worsening, the trial did not establish that the treatment helped them live significantly longer.
Summit subsequently submitted updated analyses based on longer follow-up. The company said these showed a consistent survival benefit across Asian and Western patient groups.
However, the FDA maintained that the available evidence did not establish the survival benefit needed to support approval.
Ivonescimab is an investigational PD-1 x VEGF bispecific antibody designed to target two proteins involved in cancer growth and immune evasion.
PD-1 is an immune checkpoint protein that cancer cells can exploit to evade immune attacks. Blocking this pathway can help the immune system recognize and attack cancer cells.
VEGF, meanwhile, helps tumors develop new blood vessels that supply oxygen and nutrients, supporting their growth. Blocking VEGF can interfere with this process.
By targeting both pathways, ivonescimab combines two approaches to fighting cancer: helping the immune system attack tumors and disrupting the blood supply that supports their growth.
The drug is administered through an intravenous infusion.
Ivonescimab had attracted considerable attention because of its dual-targeting approach and potential applications beyond lung cancer.
Its developers had hoped that the drug could eventually challenge Merck's Keytruda, one of the world's best-selling cancer medicines.
Several major pharmaceutical companies, including Merck and Pfizer, are also exploring therapies that combine immune checkpoint inhibition with VEGF targeting.
However, cancer researchers have cautioned against assuming that promising early results will translate into broad clinical benefits across different cancer types.
The FDA's rejection concerns a specific lung cancer indication and does not automatically determine the outcome of ivonescimab trials in other cancers.
Despite the regulatory setback, ivonescimab's development programme continues.
Summit is evaluating the drug in several other cancers, including non-small cell lung cancer, colorectal cancer, urothelial cancer and renal cell carcinoma.
The company and Akeso have reported five positive Phase III studies across their development programmes and have said they remain committed to advancing the drug.
Credit: AI-generated image
An experimental weight loss injection developed in China has produced an average weight reduction of 17.7% over 48 weeks in adults who are overweight or obese, raising the possibility of another contender entering in the rapidly expanding obesity drug market.
The drug, called ribupatide, was evaluated in a Phase 3 clinical trial published in JAMA recently. Researchers found that participants receiving the highest dose lost nearly one-fifth of their starting body weight in 11 months.
The randomised trial involved 567 adults with overweight or obesity across 55 medical centres in China. Participants did not have diabetes and their average age was 34 years.
Researchers randomly assigned them to receive once-weekly injections of ribupatide at doses of 2 mg, 4 mg or 6 mg, or a placebo. All participants also received lifestyle counselling. After 48 weeks, the average weight reduction was:
The researchers also examined how many participants lost at least 5% of their starting weight. This threshold was achieved by 68.1% of those receiving 2 mg, 88% in the 4 mg group and 85.7% in the 6 mg group, compared with 16% of participants receiving placebo.
Notably, weight loss had not clearly plateaued in the two higher-dose groups by the end of the study. This suggests that a longer treatment period may reveal further reductions.
Ribupatide, also known as HRS9531, is a dual-acting injectable medication that targets the GLP-1 and GIP hormones. These gut hormones help regulate appetite, digestion and blood glucose levels. By activating their receptors, the drug helps reduce hunger and increase feelings of fullness, helping people consume fewer calories.
This is similar to that of tirzepatide, the active ingredient in Eli Lilly's Mounjaro and Zepbound. Both medicines target GLP-1 and GIP receptors.
The trial results have drawn comparisons with existing weight loss drugs like Mounjaro and Wegovy. However, the comparisons need to be interpreted carefully.
In the SURMOUNT-1 trial, tirzepatide produced average weight loss of up to 20.9% after 72 weeks in adults with obesity or overweight without diabetes. Semaglutide 2.4 mg, marketed as Wegovy, produced an average reduction of 14.9% after 68 weeks in the STEP 1 trial.
Ribupatide's highest-dose group recorded 17.7% weight loss after 48 weeks. But these results come from separate clinical trials. A direct comparison would be needed to determine how ribupatide performs against tirzepatide or semaglutide.
Digestive problems were the most frequently reported side effectsin the ribupatide trial. Gastrointestinal side effects occurred in 47.9% of participants receiving the 2 mg dose, 58.2% in the 4 mg group and 63.1% in the 6 mg group. This compared to 23.1% of those receiving placebo.
Reported problems included nausea, vomiting and diarrhoea. Most were mild or moderate according to the findings.
The study had its limitations as the participants were relatively young, which means the findings may not apply equally to older adults. Additionally, the 48-week treatment period may not have captured the full effects of the higher doses. The study's smaller body-composition assessment also did not measure muscle strength.
Ribupatide is an investigational treatment and is not yet an approved weight-loss medication for routine use.
© $2026 Times Horizon Private Limited